Quality of Life in Patients with Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators
Study Overview
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was designed to reduce complications linked to the transvenous version (TV-ICD). This study looks at how these two devices affect patients’ quality of life.
Methodology
In the PRAETORIAN trial, patients needing an implantable cardioverter-defibrillator were randomly assigned to receive either the S-ICD or TV-ICD. Researchers used two questionnaires to assess patients’ physical and mental well-being at various stages: at the start, discharge, 12 months, and 30 months after the procedure.
Key Findings
- A total of 849 patients participated: 426 received the S-ICD and 423 received the TV-ICD.
- No significant differences in quality of life were found between the two groups.
- However, patients who received a shock from their device in the last 90 days reported lower social functioning and emotional well-being.
Conclusions
Overall, both devices showed similar quality of life outcomes. Still, receiving a shock negatively impacted patients’ quality of life, regardless of which device they had.
Clinical Relevance
Understanding these results can help improve patient care. Our platform, DocSym, simplifies access to clinical guidelines and research, helping healthcare professionals make informed decisions.
Enhancing Patient Care
Efficient healthcare operations are vital. Our mobile applications assist with scheduling, treatment monitoring, and telemedicine, facilitating better patient management.
By integrating AI into clinical workflows, we help reduce paperwork and enhance patient outcomes. Discover more at aidevmd.com.
